# At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Canonical URL: https://biopharmsignal.com/news/ADPT/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseqr-mrd-testing-across-hematology-clinical-practice-and-research
Ticker: ADPT
Company: Adaptive Biotechnologies
Source: Adaptive Biotechnologies
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.adaptivebiotech.com
## Summary

Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to

## Article Body
Over 30 scientific presentations leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to
## Recent Company News
- 2026-06-30 12:30 EST — [Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial](https://biopharmsignal.com/news/ADPT/imviva-biotech-receives-fda-ide-authorization-for-clonoseq-assay-in-tenacity-01--1f1babe9) — Source: Adaptive Biotechnologies
- 2026-06-25 13:46 EST — [Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering](https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-corporation-prices-upsized-300-million-convertible-senior-notes-offering) — Source: Adaptive Biotechnologies
- 2026-06-25 13:46 EST — [Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses](https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-announces-plan-to-separate-its-mrd-and-immune-medicine-businesses) — Source: Adaptive Biotechnologies
- 2026-06-25 13:46 EST — [Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering](https://biopharmsignal.com/news/ADPT/adaptive-biotechnologies-corporation-announces-proposed-convertible-senior-notes-offering) — Source: Adaptive Biotechnologies
- 2026-06-25 13:46 EST — [At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research](https://biopharmsignal.com/news/ADPT/at-asco-and-eha-2026-new-data-reinforce-the-pivotal-role-of-clonoseqr-mrd-testing-across-hematology-clinical-practice-and-research) — Source: Adaptive Biotechnologies
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)